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Introduction
Aging is a universal process in biological organisms that 
is characterized by a time-dependent progressive decline 
in cellular and tissue function. At the molecular and cel-
lular level, nine hallmarks have been proposed to contrib-
ute to the extremely complex, multifactorial process of 
aging: genomic instability and defects in nuclear architec-
ture, telomere attrition, epigenetic alterations and chroma-
tin remodeling, loss of proteostasis, deregulated nutrient 
sensing, mitochondrial dysfunction, cellular senescence, 
stem cell exhaustion and altered intercellular communica-
tion (Lopez-Otin et al. 2013). Aging represents a major risk 
factor for the development of several diseases including 
cancer and cardiovascular and neurodegenerative diseases 
(Campisi et al. 2011; Niccoli and Partridge 2012).
Several premature aging-like syndromes have been 
described in humans, presenting many features that resem-
ble normal aging (Navarro et al. 2006). Progeroid syn-
dromes represent a group of rare genetic disorders with 
features of premature aging (Ghosh and Zhou 2014; Pereira 
et al. 2008). They are “segmental disorders” that affect 
multiple organs and tissues and display some but not all 
symptoms observed in physiological aging (Ghosh and 
Zhou 2014; Sahin and Depinho 2010; Navarro et al. 2006). 
Most of these syndromes have been well characterized, and 
a number of associated genes and causative mutations have 
been identified in recent years (Kudlow et al. 2007; Pereira 
et al. 2008). Several heritable premature aging syndromes 
have been linked to mutations in genes encoding DNA 
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repair proteins such as Werner syndrome (WS), Cockayne 
syndrome (CS), Bloom syndrome (BS), ataxia-telangiecta-
sia (A-T), xeroderma pigmentosum (XP) and Rothmund–
Thomson syndrome (RTS), suggesting that the mainte-
nance of genome integrity has a central role in human 
aging (Navarro et al. 2006; Pereira et al. 2008). In addition, 
mutations in the mitochondrial DNA (mtDNA) and impair-
ment of mitochondrial pathways were shown to lead to the 
development of progeroid phenotypes in the mtDNA muta-
tor premature aging mouse model (Trifunovic et al. 2004; 
Bratic and Larsson 2013).
A different group of genetic premature aging disorders 
is linked to mutations in the genes encoding A-type lamins 
or lamin-processing enzymes, including Hutchinson–Gil-
ford progeria syndrome (HGPS) and restrictive dermopa-
thy (RD) (Navarro et al. 2005; De Sandre-Giovannoli 
et al. 2003). HGPS has attracted much attention not only 
because of the severity of the disease, but also due to the 
hypothesis that the expression of the disease-causing lamin 
A variant called progerin may also be linked to the normal 
aging process. While in the most common form of HGPS 
a silent point mutation in the LMNA gene affects splicing 
of prelamin A mRNA and leads to the production of the 
disease-causing lamin A variant progerin (De Sandre-Gio-
vannoli et al. 2003; Eriksson et al. 2003), the sporadic use 
of the same cryptic splice site in wild-type LMNA can lead 
to the production of mis-spliced prelamin A mRNA and 
progerin also in cells and tissues of aged healthy individ-
uals (Scaffidi and Misteli 2006; McClintock et al. 2007). 
Furthermore, HGPS and normal aging share many cellular 
phenotypes, such as abnormal nuclear shape, loss of epi-
genetic marks and increased DNA damage, as well as tis-
sue pathologies including reduced bone density and cardio-
vascular disease (Burtner and Kennedy 2010). Thus, better 
understanding of the molecular pathogenesis underlying 
progeroid syndromes can lead to a better understanding of 
the normal human aging process. In this review, we sum-
marize the genetic cause of HGPS and consequences for 
posttranslational lamin processing and lamin functions. We 
also describe potential causative disease mechanisms and 
how they may contribute to the cellular, tissue and organ-
ismal phenotypes. Finally, we briefly summarize potential 
strategies for treatment of HGPS.
Nuclear lamins: biochemistry, functions and link 
to disease
Lamins are type V intermediate filament proteins expressed 
in all metazoan cells. They are the major building blocks 
of the nuclear lamina, a complex filamentous meshwork 
underneath the inner nuclear membrane (INM) (Dechat 
et al. 2010a; Gruenbaum and Foisner 2015). Lamins share 
with their cytoskeletal counterparts the domain organiza-
tion, encompassing a ~45-nm-long central α-helical rod 
domain flanked by two globular domains (Coulombe et al. 
2001; Herrmann et al. 2007), but they contain additional 
lamin-specific motifs and domains in the C-terminus, 
such as a nuclear localization signal, a highly conserved 
immunoglobulin (Ig)-like fold and in most cases a CaaX-
box (C = cysteine, a = aliphatic residue, X = any amino 
acid) (Dechat et al. 2010a; Gruenbaum and Foisner 2015). 
Based on their sequence similarities, biochemical and 
structural properties and their expression patterns during 
development, lamins are classified into A- and B-types. 
B-type lamins are expressed throughout development, 
whereas A-type lamins are weakly or not at all expressed 
in early embryonic stages and in embryonic stem cells 
(Eckersley-Maslin et al. 2013), but they are upregulated at 
later stages during development (Gruenbaum and Foisner 
2015). In mammals, LMNB1 and LMNB2 encode the two 
major B-type lamins, lamin B1 and B2, respectively, and 
LMNB2 encodes an additional smaller germ cell-specific 
isoform (lamin B3). A-type lamins are derived from a sin-
gle LMNA gene by alternative splicing, which gives rise to 
the two major A-type isoforms (lamin A and the smaller 
splice variant lamin C) and two less abundant isoforms, 
the germ cell-specific lamin C2 and lamin AΔ10 (Broers 
et al. 2006; Dechat et al. 2010a). Lamin B1 and B2 and 
lamin A are expressed as prelamins and undergo several 
steps of posttranslational processing at their C-terminal–
CaaX sequence (Young et al. 2005). The first three process-
ing steps are common to B-type lamins and lamin A and 
include the addition of a farnesyl group to the C-terminal 
cysteine residue by farnesyltransferase (FTase) followed 
by cleavage of the -aaX tripeptide by FACE1/ZMPSTE24 
or FACE2/Rce1 proteases, and carboxymethylation of the 
farnesylated cysteine residue by the isoprenyl-cysteine-
carboxy-methylatransferase (ICMT) (Rusinol and Sinensky 
2006). The processing of B-type lamins stops at this step, 
resulting in mature lamin B with a C-terminal farnesyl- and 
carboxymethyl group. The hydrophobic farnesyl group 
mediates strong interaction with the INM, leading to the 
predominant localization of B-type lamins at the nuclear 
periphery. In contrast, farnesylated prelamin A is further 
processed by FACE1/ZMPSTE24, which removes the 15 
C-terminal amino acids including the farnesylated and car-
boxymethylated cysteine residue (Pendas et al. 2002). As 
a consequence, mature lamin A as well as lamin C, which 
lacks a CaaX-box and never becomes farnesylated, lack 
the hydrophobic farnesyl group and are therefore not only 
found at the peripheral lamina associated with the INM, 
but they can also localize to the nuclear interior (Dechat 
et al. 2010b; Kolb et al. 2011; Moir et al. 2000; Naetar 
et al. 2008). In proliferating cells, the nucleoplasmic pool 
of lamin A/C accounts for 10–15 % of total lamin A/C and 
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is highly mobile compared to lamin A/C at the periphery 
(Moir et al. 2000).
Lamins have long been known as structural components 
providing mechanical support for the nucleus (Gruenbaum 
and Foisner 2015), and recent reports showed that lamins 
define the mechanochemical properties of the nucleus 
(Osmanagic-Myers et al. 2015); lamin A is responsible for 
nuclear stiffness, and B-type lamins for nuclear elastic-
ity (Buxboim et al. 2014; Swift et al. 2013). Besides their 
mechanochemical role, lamins have a multitude of addi-
tional functions, including chromatin organization, gene 
regulation, DNA repair, and (mechano-) signaling (Amen-
dola and van Steensel 2014; Andres and Gonzalez 2009; 
Dechat et al. 2010a; Dittmer and Misteli 2011; Gruenbaum 
and Foisner 2015; Ho and Lammerding 2012).
The multitude of functions of nuclear lamins can, at 
least in part, be explained by their interactions with a 
plethora of lamin-binding proteins at the nuclear envelope 
(Brachner and Foisner 2011; Gruenbaum and Foisner 2015; 
Wilson and Foisner 2010). It is generally assumed that 
ubiquitously expressed lamins together with their differen-
tially expressed binding partners form “functional units” at 
the nuclear envelope responsible for diverse, tissue-specific 
roles of lamins (Korfali et al. 2012; Worman and Schirmer 
2015). In contrast to the huge number of lamin-binding 
proteins at the nuclear envelope, only a few proteins are 
known to interact with the mobile nucleoplasmic pool of 
lamin A/C to form “functional units” in the nuclear inte-
rior. The best-characterized interaction partner of A-type 
lamins in the nuclear interior is lamina-associated polypep-
tide (LAP) 2α (Dechat et al. 2000; Markiewicz et al. 2002; 
Dorner et al. 2006; Naetar et al. 2008), a unique isoform of 
the LAP2 family. Unlike the other LAP2 isoforms, which 
are integral membrane proteins of the INM, LAP2α lacks 
a transmembrane domain and localizes in the nuclear inte-
rior, where it interacts with and stabilizes nucleoplasmic 
lamin A/C (Dechat et al. 2000; Naetar et al. 2008). Nucleo-
plasmic lamin A/C–LAP2α complexes have been impli-
cated in the retinoblastoma protein-mediated regulation of 
cell proliferation and differentiation of tissue progenitor 
cells (Dorner et al. 2006; Markiewicz et al. 2002; Naetar 
et al. 2008) and in chromatin organization (Bronshtein 
et al. 2015; Zhang et al. 2013).
Given the multitude of functions of the lamins, it is 
not surprising that mutations in lamins and lamin-binding 
proteins are associated with a variety of human diseases 
exhibiting complex patterns of tissue-specific pathologies 
(Broers et al. 2006; Worman 2012). The majority of dis-
eases are caused by mutations in the LMNA gene and are 
collectively termed laminopathies. Until today more than 
500 mutations have been described in LMNA (www.umd.
be/LMNA/) that give rise to four major groups of diseases 
with overlapping pathologies, including striated muscle 
diseases, lipodystrophic syndromes, peripheral neuropathy 
and accelerated aging disorders (Worman 2012).
Hutchinson–Gilford progeria syndrome: genetics 
and cellular and clinical phenotypes
Hutchinson–Gilford progeria syndrome (HGPS) is an 
extremely rare sporadic autosomal-dominant genetic dis-
order affecting 1 in 4–8 million newborns and displays 
phenotypic features of premature aging (Ghosh and Zhou 
2014; Gordon et al. 2014). Children with HGPS appear 
normal at birth but start to exhibit many distinctive clini-
cal features within the first year of life. Classical progeria 
symptoms include severe growth retardation, loss of hair 
and subcutaneous fat, prominent eyes and scalp veins, 
aged-looking skin, joint stiffness and reduced bone density. 
As children get older they suffer from osteoporosis, ath-
erosclerosis and cardiovascular diseases as the most severe 
aspect of the disease. HGPS patients die at an average age 
of 14 years due to myocardial infarction, heart failure or 
progressive atherosclerosis (Cau et al. 2014; Kieran et al. 
2007; Muchir and Worman 2010).
Classical HGPS is caused by a de novo heterozygous 
mutation (1824C>T, p.G608G) in exon 11 of LMNA (De 
Sandre-Giovannoli et al. 2003; Eriksson et al. 2003), which 
activates a cryptic splice donor site, resulting in the produc-
tion of a prelamin A mRNA that contains an internal dele-
tion of 150 base pairs. This transcript is translated into a 
mutant lamin A protein termed progerin, which harbors a 
deletion of 50 amino acids within its C-terminus including 
the FACE1/ZMSPTE24 cleavage site (Eriksson et al. 2003). 
As a consequence, progerin cannot undergo the final prote-
olytic processing step and permanently retains the C-termi-
nal farnesyl group, leading to its stable association with the 
INM and predominant localization at the nuclear periphery 
(Dechat et al. 2007; Davies et al. 2009).
Progerin is expressed in multiple tissues, mostly of mes-
enchymal origin including skin, bone, skeletal muscle, 
adipose tissue, heart and large and small arteries (Gordon 
et al. 2014). Expression of progerin induces various cellu-
lar defects in a dominant-negative manner, including highly 
lobulated nuclei with thickened lamina, loss of peripheral 
heterochromatin, accumulation of DNA damage, telomere 
aberrations and mitochondrial dysfunction, leading to dif-
ferentiation defects and premature cellular senescence 
(Bridger and Kill 2004; Brunauer and Kennedy 2015; 
Goldman et al. 2004; Gonzalo and Kreienkamp 2015; 
McCord et al. 2013; Scaffidi and Misteli 2008; Shumaker 
et al. 2006; Vidak et al. 2015). In addition, progerin expres-
sion leads to decreased expression levels of lamin B1, het-
erochromatin protein 1 α (HP1α) and LAP2α, and loss of 
nucleoplasmic lamins (Fig. 1) (Cenni et al. 2011; Scaffidi 
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and Misteli 2005; Miller et al. 2013; Scaffidi and Misteli 
2008; Vidak et al. 2015). These changes together with the 
abnormal nuclear morphology are often used as cellular 
disease markers to test therapeutic strategies in cell and 
mouse models (Cao et al. 2011b; Capell et al. 2005; Fong 
et al. 2006; Scaffidi and Misteli 2005).
In addition to the classical 1824C>T HGPS mutation, 
other heterozygous, homozygous or compound heterozy-
gous mutations in LMNA have been reported, such as T10I, 
A57P, L59R, R133L, L140R, S143F, E145K, V169fsX176, 
D300N, E578V and R644C and c.412G>A (Kirschner 
et al. 2005; Csoka et al. 2004; Chen et al. 2003; Caux et al. 
2003; Jacob et al. 2005; Mory et al. 2008; McPherson et al. 
2009; Doh et al. 2009; Renard et al. 2009; Doubaj et al. 
2012; Kane et al. 2013), all causing atypical progeroid 
syndromes (APS). APS mutations affect similar tissues 
(bone, skin, hair and body fat) and cause similar patholo-
gies (growth retardation, alopecia, tight skin and beaked 
nose) as classical HGPS, but the course and severity of 
the symptoms vary greatly (Garg et al. 2009; Doubaj et al. 
2012). Compound heterozygous mutations in FACE, lead-
ing to the complete loss of function of ZMPSTE24 protease 
and accumulation of farnesylated prelamin A causes auto-
somal recessive restrictive dermopathy (RD), a progeroid 
syndrome associated with neonatal death (Navarro et al. 
2005). In 2011, a new autosomal recessive syndrome was 
identified and named Nestor–Guillermo progeria syndrome 
(NGPS) (Cabanillas et al. 2011). Patients with NGPS dis-
play several pathologies similar to HGPS but with a slow 
clinical course and relatively long survival. NGPS is 
caused by a homozygous missense mutation in BANF1 that 
encodes barrier-to-autointegration factor (BAF), a chroma-
tin protein, which directly interacts with lamins and lamin-
binding proteins and has been implicated in chromatin 
organization (Margalit et al. 2007).
Mouse models of HGPS
In the search for molecular disease mechanisms of HGPS, 
several progeroid mouse models have been created. 
One of the first of these mouse models was generated by 
knocking-in a mutant Lmna allele (LmnaHG) that produces 
exclusively progerin but no wild-type lamin A and lamin 
C (Yang et al. 2005). This knock-in mouse model displays 
phenotypes similar to HGPS children including loss of hair 
(alopecia) and subcutaneous fat, osteoporosis and prema-
ture death, but no cardiovascular defects were reported. In 
contrast, a transgenic mouse model that carries the mutated 
G608G human LMNA allele on a bacterial artificial chro-
mosome (G608G BAC) develops progressive loss of vas-
cular smooth muscle cells (VSMCs), a feature described 
also in HGPS patients, but did not show most of the other 
pathologies (Varga et al. 2006). Another mouse model, 
in which a point mutation in Lmna caused loss of exon 9 
























Fig. 1  Progerin expression causes loss of nucleoplasmic lamin A/C 
and LAP2α in primary HGPS fibroblasts. Immunofluorescence analy-
sis of wild-type (WT) and HGPS primary human fibroblasts using anti-
progerin (red), anti-lamin A/C (green) and anti-LAP2α (green) anti-
bodies shows significant decrease in the nucleoplasmic pool of A-type 
lamins and LAP2α levels upon progerin expression. Scale bar 10 µm
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phenotypes overlapping with HGPS (Mounkes et al. 2003; 
Hernandez et al. 2010), but the mechanism is still unclear 
and may differ from that of the classical HGPS.
These mouse models phenocopy some of the phenotypes 
observed in the HGPS patients, but they do not recreate the 
exact molecular changes occurring at the LMNA locus in 
HGPS patients. Therefore, Osorio et al. created a mouse 
knock-in strain that carries a HGPS mutation in the mouse 
Lmna gene (LmnaG609G; 1827C>T; Gly609Gly) and pro-
duces progerin due to abnormal splicing of the endogenous 
Lmna mRNA like in HGPS patients (Osorio et al. 2011). 
These mice phenocopy the main clinical manifestations of 
human HGPS and open new avenues towards investigating 
the splicing defect in HGPS and identification of drugs that 
may correct faulty splicing of prelamin A mRNA in HGPS.
In addition to these transgenic mice expressing prog-
erin ubiquitously, several mouse models with tissue-spe-
cific progerin expression have been generated. A trans-
genic mouse model that contains a human G608G LMNA 
minigene mutant under the control of a tet-operon (teto-
pLAG608G) allowed tissue-specific and inducible expression 
of progerin by crossing them with transgenic mice express-
ing the transactivator in specific tissues (Sagelius et al. 
2008). Expression of progerin in keratin 5-expressing cells 
in the epidermis caused loss of subcutaneous fat, fibrosis of 
the dermis, incomplete development of sebaceous glands, 
dental problems, hair thinning, decreased stem cell popu-
lation in epidermal tissues and impaired wound healing 
ability, supporting the hypothesis that an impaired regen-
eration capacity of epidermal stem cells may contribute to 
the HGPS phenotype (Rosengardten et al. 2011). The oste-
oblast-specific expression of progerin reduced bone density 
and caused spontaneous fractures most likely due to an 
abnormal osteoblast differentiation (Schmidt et al. 2012). 
In contrast, expression of progerin in the aged brain, which 
usually expresses low levels of lamin A/C, caused some 
structural nuclear abnormalities but no signs of impaired 
brain function were detected (Baek et al. 2015).
Deletion of Zmpste24, the metalloproteinase involved 
in the posttranslational maturation of prelamin A, results 
in the expression of farnesylated prelamin A and produces 
various progeroid phenotypes in mice. Zmpste24−/− mice 
are normal at birth, but within 4–6 weeks of age they 
start to display many of the progeroid phenotypes such as 
growth retardation, alopecia, loss of adipose tissue, multi-
ple spontaneous bone fractures, abnormal nuclear morphol-
ogy and premature death, as well as muscular dystrophy 
and dilated cardiomyopathy (Bergo et al. 2002; Pendas 
et al. 2002). The latter phenotypes may also be linked to 
the fact that no mature lamin A is produced in these mice, 
while HGPS phenotypes may be caused by the accumula-
tion of farnesylated prelamin A. In support of this hypoth-
esis, blocking prelamin A farnesylation in these mice by 
farnesyltransferase inhibitors (FTIs) improves some of 
the HGPS phenotypes (Fong et al. 2006). Furthermore, a 
knock-in mouse model that exclusively expresses non-
farnesylated prelamin A (LmnanPLAO/nPLAO) shows no prog-
eroid phenotypes but develops severe cardiomyopathy 
(Davies et al. 2010). In contrast, observations in LmnaHG/+ 
mice that FTI treatment ameliorates but not completely 
abolishes progeria phenotypes suggested that the non-
farnesylated form of progerin may retain some toxic fea-
tures relevant for HGPS. To test this hypothesis, a mouse 
model exclusively expressing the non-farnesylated form 
of progerin (LmnanHG) was generated by replacing the 
cysteine in the CaaX motif in the LmnaHG allele with a ser-
ine (CSIM → SSIM). Interestingly, homozygote and het-
erozygote LmnanHG mice showed similar, but less severe 
progeroid phenotypes than those described for LmnaHG 
mice (Yang et al. 2008). To exclude that the cysteine-to-
serine substitution may itself be toxic, an alternative non-
farnesylated progerin-expressing mouse model was gener-
ated by deleting the isoleucine in the CSIM motif to create 
a protein ending in CSM rather than SSIM (LmnacsmHG). 
Surprisingly, LmnacsmHG mice showed no noticeable prog-
eroid defects, suggesting that cysteine-to-serine substitu-
tion in the LmnanHG mouse model may be toxic, although 
the authors do not exclude the possibility that toxicity of 
progerin is linked to the 50 amino acid deletion in its C-ter-
minus independent of farnesylation and the deletion of the 
isoleucine in CSIM may neutralize the toxicity of the pro-
tein (Yang et al. 2011b).
Molecular and cellular mechanisms contributing 
to the HGPS pathologies
HGPS-causing mutations have been shown to affect many 
fundamental cellular processes, but how these contribute 
to the described pathologies is not completely understood. 
In most cases, we do not even know the detailed molecular 
mechanisms how progerin expression affects the molecular 
processes found to be impaired in HGPS. However, based 
on what is known about lamin A/C and progerin biochem-
istry, function and interactions (Kubben et al. 2010a, b), 
one may hypothesize about potential pathways and mecha-
nisms (Fig. 2) discussed below.
Mechanical defects in HGPS
The presence of the farnesyl group in progerin is thought 
to be a predominant toxic feature in the pathogenesis of 
the disease. In healthy cells, A- and B-type lamins form 
distinct homopolymers and micro-domains at the nuclear 
periphery (Shimi et al. 2008), but this segregation may be 
lost in HGPS cells (Delbarre et al. 2006) due to the stable 
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association of permanently farnesylated progerin with the 
membrane (Dechat et al. 2007). Progressive progerin accu-
mulation at the INM during cellular aging of HGPS cells 
(Eriksson et al. 2003; Fong et al. 2006; Goldman et al. 
2004; Varela et al. 2005) leads to immobilization of wild-
type lamin A at the lamina, thickening and increased stiff-
ness of the lamina, prominent lobulation of the nuclear 
envelope, and clustering of nuclear pores (Dahl et al. 2006; 
Goldman et al. 2004). Overall, these alterations disrupt the 
structural and functional integrity of the nuclear lamina 
and may render cells more susceptible to damage through 
physical stress (Verstraeten et al. 2007; Zhang et al. 2011). 
While in wild-type cells nuclei respond to shear stress 
by up-regulation and re-distribution of A-type lamins 
(Buxboim et al. 2014; Philip and Dahl 2008; Swift et al. 
2013), this rearrangement does not work properly in HGPS 
cells (Dahl et al. 2006). This defect is of particular impor-
tance in tissues that are exposed to mechanical stress such 
as vasculature, bone and joints, which also present some 
of the most prominent pathologies in HGPS (Gordon et al. 
2014; Zhang et al. 2011). In accordance, HGPS skin fibro-
blasts and VSMCs display increased mechanosensitivity 
under biomechanical strain (Verstraeten et al. 2008), which 
may then lead to the observed severe depletion of arterial 
VSMCs in progeria patients and some progeria mouse 
models (Stehbens et al. 1999; Varga et al. 2006).
Altered adaptation of progerin-expressing cells to 
high sheer stress may also be caused by progerin’s nega-
tive effect on the expression of many proteins involved in 
mechanotransduction and cytoskeletal organization, as well 
as extracellular matrix proteins (ECM) (Song et al. 2014; 
Brassard et al. 2015). In accordance with this, accumulation 
of progerin in the ascending aorta of LmnaG608G knock-in 
mice causes reduced expression of the cytoskeleatal protein 
vimentin (Song et al. 2014). As vimentin has a major role 
in maintaining cellular integrity and affects apoptotic path-
ways (Song et al. 2014; Moisan and Girard 2006; Barker 
et al. 2010), the impaired vimentin expression may lead to 
Fig. 2  Cellular functions affected by the expression of the lamin A 
mutant protein progerin. Progerin accumulates at the nuclear mem-
brane/lamina leading to reduced levels of nucleoplasmic lamin A/C–
LAP2α. These changes in lamin dynamics affect mechanical proper-
ties and mechanosignaling, lead to dissociation of heterochromatic 
lamina-associated domains (LADs) in the genome from the lamina, 
and impair signaling pathways and gene expression, all contributing 
to defects in self-renewal and differentiation of adult stem cells, the 
production of a faulty extracellular matrix (ECM) and cell senescence
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defects in mechanotransduction and mechanosignaling in 
progerin-expressing VSMCs (Song et al. 2014; Brassard 
et al. 2015). Furthermore, progerin expression was shown 
to impair linker of the nucleoskeleton and cytoskeleton 
(LINC) complexes at the nuclear envelope through the 
stabilization and accumulation of SUN1, a LINC compo-
nent in the INM, and reducing SUN1 mobility (Chen et al. 
2014). As the LINC complex is essential for nucleocy-
toskeletal coupling and mechanotransduction (Osmanagic-
Myers et al. 2015), an impaired LINC complex may further 
contribute to impaired shear stress response in the vascula-
ture of HGS patients.
Impaired chromatin organization
A-type lamins can directly interact with DNA and his-
tones (Gruenbaum and Foisner 2015), and together with 
a number of lamin A-binding chromatin proteins, such as 
members of the LEM domain protein family (Brachner and 
Foisner 2011; Solovei et al. 2013), they have been impli-
cated in higher-order chromatin organization, heterochro-
matin formation and epigenetic regulation (Amendola and 
van Steensel 2014; Dechat et al. 2009; Gonzalez-Suarez 
and Gonzalo 2010). A-type lamins contribute to the teth-
ering of heterochromatic genomic regions, termed lamina-
associated domains (LADs) to the nuclear lamina (Meule-
man et al. 2013; Peric-Hupkes et al. 2010) but they also 
interact with promoter regions of genes, thereby affecting 
gene expression during cell differentiation (Lund et al. 
2013; Ronningen et al. 2015).
It is therefore not surprising that progerin-expressing 
HGPS nuclei display significant changes in chromatin, 
such as loss of peripheral heterochromatin, a decrease in 
the repressive histone marks H3K9me3 and H3K27me3 
and an increase in H4K20me3 (Columbaro et al. 2005; 
Kubben et al. 2012; McCord et al. 2013; Scaffidi and Mis-
teli 2005; Shumaker et al. 2006). It is currently unknown 
how progerin affects chromatin organization mechanisti-
cally, but several reports showing an effect of progerin on 
epigenetic modifier and chromatin regulator proteins may 
provide clues towards potential mechanisms. For exam-
ple, progerin expression causes upregulation of the meth-
yltransferase Suv39h1, while Suv39h1 depletion delays 
senescence of HGPS cells and prolongs lifespan of Zmp-
ste24−/− mice (Liu et al. 2013). Furthermore, progerin-
expressing cells have reduced levels of heterochromatin 
protein 1 (HP1) α (Scaffidi and Misteli 2008) and of sev-
eral proteins of the nucleosome remodeling NuRD com-
plex (Pegoraro et al. 2009; Meshorer and Gruenbaum 2009; 
Prokocimer et al. 2013). Interestingly, inactivation of the 
NuRD complex in wild-type cells can also induce aging-
associated chromatin defects resembling those observed 
in HGPS patients. Changes in chromatin organization and 
epigenetic regulation in progeria cells may in turn have a 
profound impact on gene expression and genome stability, 
thereby contributing to many disease phenotypes (Prokoci-
mer et al. 2013).
Most of the lamin A/C chromatin interaction studies so 
far have focused on the nuclear lamina, but, given the dual 
location of A-type lamins at the nuclear lamina and in the 
nuclear interior, it is tempting to speculate that nucleoplas-
mic lamins together with their binding partner LAP2α may 
interact with and regulate chromatin throughout the nucleus 
(Gesson et al. 2014). In support of this, a recent study 
demonstrated that only 30 % of all cellular LADs in the 
genome associate with the nuclear envelope in a given cell, 
while the rest localizes in the nuclear interior, but LADs are 
stochastically reshuffled to the nuclear lamina in each cell 
cycle (Kind et al. 2013). This indicates that lamin A–LAD 
interaction may also occur in the nuclear interior. In line 
with this model, lamin A/C-deficient cells show increased 
mobility of chromatin in the nuclear interior (Bronshtein 
et al. 2015), indicating that lamin A may cross-link chro-
matin fibers. Moreover, several recent findings indicate that 
A-type lamins interact also with genomic regions outside 
of the LADs (Lund et al. 2013, 2015; Ronningen et al. 
2015). Furthermore, LAP2α has been found to interact with 
chromatin at a genome-wide level and to affect chromatin 
interaction of high-mobility group N protein 5 (HMGN5), 
a non-histone protein involved in higher-order chromatin 
organization (Zhang et al. 2013). As progerin expression 
reduces levels of nucleoplasmic lamin A/C and LAP2α 
(Dahl et al. 2006; Scaffidi and Misteli 2005; Vidak et al. 
2015), it is conceivable that chromatin organization in the 
nuclear interior is particularly affected in HGPS. In support 
of this, re-expression of LAP2α in HGPS cells was found 
to rescue proliferation of the cells, most likely due to the 
rescue of the impaired chromatin organization at telomeres 
(Chojnowski et al. 2015) and at genomic regions harboring 
ECM genes (Vidak et al. 2015).
Genome instability
Progerin expression may also affect genome stability by 
negatively affecting DNA damage repair pathways (Liu 
et al. 2005). HGPS cells and cells derived from Zmp-
ste24−/− mice display impaired recruitment of the DNA 
double-strand break (DSB) repair factors p53-binding 
protein 1 (53BP1) and Rad50 and Rad51 to the sites of 
DNA damage (Liu et al. 2005; Manju et al. 2006), result-
ing in the accumulation of DSBs (Musich and Zou 2011; 
Richards et al. 2011). Progerin expression also affects 
the expression and localization of the nucleotide excision 
repair protein XPA (Xeroderma Pigmentosum comple-
mentation group A) at DNA lesions, resulting in persistent 
activation of DNA damage response checkpoint kinases 
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ataxia-telangiectasia-mutated (ATM) and ATM and Rad3-
related (ATR) protein (Manju et al. 2006; Gonzalo and 
Kreienkamp 2015). Persistent DNA damage in turn acti-
vates tumor suppressor p53 and promotes senescence, one 
of the phenotypes described as hallmarks of HGPS (Col-
lado et al. 2007).
Deficiencies in DSB repair and telomere dysfunction 
are major contributors to genome instability in aging cells 
(Hoeijmakers 2009; Blasco 2005). Dysfunctional telomeres 
are recognized as DSBs and activate the non-homologous 
end joining (NHEJ) repair pathway (di Fagagna et al. 2003; 
Gonzalo and Kreienkamp 2015). Persistent telomere dys-
function and shortening of telomeres below a critical length 
cause permanent growth arrest known as replicative senes-
cence (Gonzalo and Kreienkamp 2015). HGPS cells were 
found to undergo accelerated telomere shortening when 
grown in culture (Decker et al. 2009), and ectopic expres-
sion of progerin in wild-type fibroblasts leads to accumu-
lation of DNA damage at telomeres (Benson et al. 2010; 
Cao et al. 2011a), both resulting in proliferation arrest 
and senescence. Accordingly, re-expression of telomer-
ase improves proliferation and extends HGPS cellular 
lifespan (Kudlow et al. 2007; Benson et al. 2010; Cho-
jnowski et al. 2015), suggesting that telomere dysfunction 
underlies genomic instability and premature senescence 
in progerin-expressing cells (Gonzalo and Kreienkamp 
2015). The molecular mechanisms leading to telomere dys-
function upon progerin expression are poorly understood. 
Recent studies suggest a role of LAP2α in stabilizing tel-
omere and chromatin structure by increasing the epigenetic 
H3K27me3 histone mark, preventing progerin-associated 
DNA damage and rescuing premature senescence (Cho-
jnowski et al. 2015).
Altered regulation of signaling pathways
Lamins serve as scaffolds for various signaling molecules 
and transcription factors, thereby regulating their activity 
(Gruenbaum and Foisner 2015; Osmanagic-Myers et al. 
2015). This scaffolding function has a dual role. On the one 
hand, lamins serve as a platform enabling efficient activa-
tion of signaling molecules, such as the extracellular-signal 
regulated kinase (ERK)-dependent activation of transcrip-
tion factor c-fos at the lamina (Gonzalez et al. 2008). On the 
other hand, they sequester various transcription factors and 
their regulating molecules to the nuclear periphery attenu-
ating their function on target genes (Ivorra et al. 2006; 
Scaffidi and Misteli 2008). Therefore, it is not surprising 
that progerin expression causes misregulation of various 
signaling pathways (Prokocimer et al. 2013) as shown in 
numerous examples; the molecular mechanisms, however, 
remain mostly obscure. Fibroblasts from the Lmna Δ9 pro-
geria mouse model have reduced Wnt/β-catenin signaling 
causing defects in the expression of ECM genes (Her-
nandez et al. 2010). Similarly, hair follicle stem cells in 
Zmpste24−/− mice have reduced levels of active β-catenin 
(Espada et al. 2008). As wnt signaling is important for car-
tilage and bone development, an impaired wnt signaling 
can contribute to the bone phenotype in HGPS patients. 
Notch signaling, another important pathway for the regula-
tion of cell fate and stem cell differentiation during osteo-
genesis and adipogenesis (Hori et al. 2013), is also affected 
in progerin expressing cells (Scaffidi and Misteli 2008). 
Here, some insight into the potential molecular mechanism 
of progerin’s effect on Notch-signaling has been provided: 
Sequestration of the Notch co-activator SKIP (Ski-interact-
ing protein) by wild-type lamins is impaired by progerin, 
leading to increased activation of major Notch downstream 
effectors (HES1, HES5, HEY1 and TLE1) (Scaffidi and 
Misteli 2008). NF-κB, an important transcription factor 
activated as a response to damage, stress and inflammation 
(Ghosh and Hayden 2008) and during aging (Tilstra et al. 
2012), was found to be hyperactivated in progeroid mice 
(Zmpste24−/− and LmnaG609G knock-in mice) (Osorio et al. 
2012). Crossing Zmpste24−/− mice with transgenic mice 
displaying reduced NF-κB signaling (haploinsufficient for 
the p65 (RelA) NF-κB subunit, RelA+/−) or treatment of 
mice with the NF-κB inhibitor sodium salicylate extended 
life span and rescued skin and immunological phenotypes 
(Kawahara et al. 2009; Osorio et al. 2012).
Complexes of nucleoplasmic A-type lamins and LAP2α 
interact directly with retinoblastoma protein (pRb) a major 
regulator of cell proliferation (Markiewicz et al. 2002; 
Dorner et al. 2006), thereby affecting pRb localization 
and stability (Johnson et al. 2004; Andres and Gonzalez 
2009; Nitta et al. 2007) and expression of pRb target genes 
(Dorner et al. 2006; Naetar et al. 2008). Genome-wide 
expression studies in primary HGPS-derived dermal fibro-
blasts revealed an impaired pRb signaling network (Marji 
et al. 2010). Thus, the loss of nucleoplasmic lamin A/C and 
LAP2α in HGPS cells (Vidak et al. 2015) may be linked 
to a deregulation of the pRb pathway in HGPS, leading to 
impaired regulation of tissue stem cells (Naetar et al. 2008). 
An impairment of pRb signaling may also be linked to the 
reduced levels of heterochromatic histone marks in HGPS 
in view of the described role of pRb in stabilizing histone 
methylation (Gonzalo et al. 2005).
Altered regulation of adult stem cells
Adult stem cells constantly replace non-functional and 
dying cells in many tissues and an age-related decline in 
their regenerative capacity is an important factor in biologi-
cal aging (Brassard et al. 2015). Several lines of evidence 
suggest that A-type lamins may be involved in the regula-
tion of proliferation and differentiation of mesenchymal 
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stem cells (MSCs) as well as tissue progenitor cells (Gotz-
man and Foisner 2006; Pekovic et al. 2007). MSCs are 
adult stem cells important for the regeneration of many 
tissues profoundly affected in HGPS such as bone, skin, 
muscle and adipose tissue (Scaffidi and Misteli 2008; 
Dreesen and Stewart 2011; Halaschek-Wiener and Brooks-
Wilson 2007). Naive MSCs derived from HGPS patients 
express low progerin levels in vivo, but accumulate signifi-
cant amounts of progerin with increasing passages in vitro 
(Wenzel et al. 2012). Both, adult stem cell self-renewal and 
differentiation may be affected in HGPS through impaired 
signaling and chromatin organization as described above. 
In line with this, Zmpste 24−/− and tetop-LmnaG608G;K5tTA+ 
progeria mouse models (see in chapter mouse models) dis-
play decreased numbers and altered proliferative capacity 
of epidermal stem cells (Espada et al. 2008; Rosengard-
ten et al. 2011) and muscle-derived stem/progenitor cells 
(MDPSCs) (Lavasani et al. 2012). Interestingly, intraperi-
toneal administration of MDPSCs from young wild-type 
mice to progeroid mice leads to significant extension of life 
span and health span (Lavasani et al. 2012), further sup-
porting the hypothesis that an impaired stem cell regulation 
contributes to premature aging. Postnatal, but not embry-
onic fibroblasts, derived from the Lmna∆9 progeria mouse 
model, show proliferative arrest and premature senescence 
(Hernandez et al. 2010). Why this phenotype is detectable 
only in postnatal cells remains unknown, but it is likely 
linked to an impaired extracellular matrix (ECM) produc-
tion (Hernandez et al. 2010).
Based on the emerging findings in HGPS, it is tempting 
to speculate that a misbalance in stem cell self-renewal and 
differentiation coupled with increased mechanical sensitiv-
ity could lead to stem cell exhaustion and inefficient repair 
of the damaged tissues, contributing to many of the pheno-
types in HGPS (Gotzman and Foisner 2006).
ECM‑mediated HGPS mechanisms
Several recent findings led to the newly emerging concept 
that progerin expression may lead to impaired expression 
of ECM components and formation of a faulty ECM, which 
in turn may be causative for many of the cellular pheno-
types observed in HGPS. The ECM is well known to have 
a major role in cell proliferation, differentiation, cell adhe-
sion and migration, and cell survival (Gattazzo et al. 2014; 
Humphrey et al. 2014), and ECM production is also com-
promised during physiological aging (Yang et al. 2011a). 
Abnormal ECM production and rearrangement during 
development and tissue homeostasis result in many patho-
logical processes including tissue fibrosis and cancer.
Gene expression analyses in HGPS patient fibroblasts 
showed a profound deregulation of ECM components 
(Csoka et al. 2004), including decreased levels of ECM 
remodeling enzymes such as metaloproteinases (MMPs) 
(Harten et al. 2011; Vidak et al. 2015) and increased lev-
els of type IV and VI collagen and fibronectin (Colige et al. 
1991; Maquart et al. 1988; Song et al. 2014). The impor-
tance of a faulty ECM in the development of HGPS phe-
notypes is supported by several observations: Proliferation 
of human cells expressing progerin (Vidak et al. 2015) and 
of mouse adult fibroblasts derived from LmnaΔ9 progeria 
mice (Hernandez et al. 2010) is rescued upon growth on 
ECM derived from wild-type cells. The most convincing 
data supporting the role of the ECM in disease develop-
ment in vivo comes from Zmpste24 mosaic mice containing 
similar proportion of Zmpste24-deficient (prelamin A-accu-
mulating) and Zmpste24-proficient (mature lamin A-con-
taining) cells in tissues (de la Rosa et al. 2013). Surpris-
ingly, these mice develop normally and maintain the same 
proportion of mutant versus wild-type cells in their tissues 
throughout life, indicating that progeroid Zmpste24−/− cells 
develop normally in a background providing normal ECM 
and possibly other extrinsic factors.
Overall, a deregulation of ECM production and remod-
eling could account for both an impaired proliferation and 
differentiation of osteoblasts and chondrocytes during car-
tilage development (Muchir and Worman 2010), as well as 
an excessive ECM deposition in the vascular system caus-
ing increased arterial stiffness in HGPS (Olive et al. 2010).
Therapeutic approaches in progeria
Therapeutic approaches for HGPS treatment can be envis-
aged to work at different levels from genes to tissues, 
including approaches to correct protein function, RNA 
splicing and mutations in the LMNA gene, to cell replace-
ment strategies and treatments to reverse the cellular phe-
notypes (Gordon et al. 2014). The first therapy developed 
for HGPS and already tested in clinical trials (Gordon et al. 
2012) aimed at correcting the mutant protein. As the pres-
ence of the farnesyl group in progerin was proposed to be 
the predominant deleterious and toxic component, efforts 
were put into treatments blocking progerin farnesylation 
through pharmacologically targeting the isoprenoid bio-
synthesis pathway (Young et al. 2005; Cau et al. 2014). 
The initial treatment used drugs called farnesyltransferase 
inhibitors (FTIs), previously developed as potential anti-
cancer drugs, which improve some disease parameters in 
cultured cells (e.g., nuclear shape and proliferation) and 
progeria mouse models (Fong et al. 2006; Toth et al. 2005; 
Yang et al. 2005). Based on these preclinical tests a pro-
spective clinical trial was commenced at Boston Children’s 
Hospital from 2007 to 2009 including 26 HGPS patients 
(Gordon et al. 2012). Administration of the FTI drug lona-
farnib improved weight gain, bone structure and vascular 
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stiffness, with some of the HGPS patients developing mild 
drug-related side effects (Gordon et al. 2012). After the ini-
tiation of the first clinical trial, it was demonstrated that an 
alternative prenylation pathway called geranyl geranylation 
may be activated in the presence of FTIs, offering possi-
ble explanations for the only moderate efficiency of the FTI 
treatment in preclinical trials (Yang et al. 2008). Therefore, 
the pharmacological strategy was adjusted and tested in the 
Zmpste 24−/− progeria mouse model, using a combined 
aminobisphosphonate (zoledronic acid) and statin (pravas-
tatin) treatment, inhibiting farnesyl-pyrophosphatase syn-
thase and the HMG-CoA reductase, respectively (Varela 
et al. 2008). Based on promising results in preclinical tri-
als using the Zmpste 24−/− progeria mouse model (Varela 
et al. 2008), a second clinical trial combining statins and 
aminobisphosphonates was initiated from 2008 to 2013 in 
Marseille’ La Timone Children’s Hospital, but the results of 
the study are not published yet (Cau et al. 2014).
Another approach for treatment aims at reducing prog-
erin protein levels rather than blocking progerin farnesyla-
tion. Two major cellular mechanisms are involved in remov-
ing misfolded, mutant or aggregated proteins, proteasomal 
degradation and autophagy. Although a detailed study on 
potential pathways involved in progerin degradation has not 
been done so far, several observations suggest that progerin 
may be removed by activating macroautophagy. Autophagy 
is a cytoplasmic degradation machinery that targets dam-
aged proteins and organelles to lysosomal degradation and 
is upregulated in times of stress such as starvation to pro-
vide a source of amino acids (Tanida et al. 2008). Treat-
ment with rapamycin, an inhibitor of the mammalian target 
of rapamycin (mTOR) pathway, upregulates autophagy and 
extends life span from yeast to mammals (Johnson et al. 
2013; Jung et al. 2010; Madeo et al. 2010). Rapamycin 
treatment of cultured HGPS cells increases progerin clear-
ance by macroautophagy-related pathways and reduces 
some of the disease phenotypes, such as lobulated nuclei, 
LAP2α levels and DNA damage (Cao et al. 2011b; Cenni 
et al. 2011). Interestingly, it has been suggested that FTIs 
may indirectly affect mTOR by inhibiting the farnesylation 
of Rheb GTPase, an upstream activator of mTOR (Hanker 
et al. 2010).
Sulforaphane, an antioxidant derived from crucifer-
ous vegetables, which stimulates proteasome activity and 
autophagy in normal and HGPS fibroblast cultures, was 
also found to enhance progerin clearance by autophagy 
and to reverse the cellular hallmarks of HGPS (Gabriel 
et al. 2015). Furthermore, two recent studies suggested that 
retinoids alone (Kubben et al. 2015) or in a combination 
with rapamycin (Pellegrini et al. 2015) lower the amount 
of progerin and rescue progeroid phenotypes in cultured 
cells. These findings together suggest that compounds act-
ing by decreasing progerin levels in the cell could represent 
a potent tool for new treatments. Autophagy-activating 
drugs could be particularly beneficial in progeria treatment, 
but careful in vivo analyses have to be conducted before 
including them in clinical trials.
An RNA-targeting therapeutic strategy aims at elimi-
nating or inhibiting alternative splicing of progerin pre-
mRNA. Introduction of a short (25-mer) antisense mor-
pholino oligonucleotide that can sterically block the cryptic 
splice site in exon 11 of progerin pre-mRNA resulted in a 
concentration-dependent decrease in progerin mRNA and 
protein levels and in the reversion of cellular phenotypes 
in cultured HGPS cells (Scaffidi and Misteli 2005). A simi-
lar strategy was successfully tested in vivo in Zmpste24−/− 
and LmnaG609G/G609G progeria mice, resulting in improved 
body weight, extended lifespan and improvement of sev-
eral HGPS phenotypes (Osorio et al. 2011). This finding, 
together with the increasing evidence that the use of oligo-
nucleotides for correction of splicing defects has growing 
therapeutic applications, initiated a set up of a new clinical 
trial that is currently under design (Cau et al. 2014).
Finally, a few approaches have been described to tar-
get cellular HGPS phenotypes. Resveratrol, an activator of 
SIRT1, a deacetylase involved in many cellular processes 
(Lavu et al. 2008), was found beneficial in the treatment of 
Zmpste24−/− mice (Liu et al. 2012). Resveratrol treatment 
was previously shown to increase life span in yeast, worms, 
and flies and to enhance health span in rodents (Baur et al. 
2006; Howitz et al. 2003; Milne et al. 2007; Wood et al. 
2004). The mechanism of the beneficial effect of resvera-
tol in HGPS mice is unclear, but it has been shown that 
SIRT1 interacts with lamin A in wild-type cells (Liu et al. 
2012). In the presence of progerin or prelamin A, SIRT1 
exhibits reduced association with the nuclear matrix and 
decreased deacetylase activity, leading to rapid depletion of 
adult stem cells in Zmpste24−/− mice. Resveratrol enhances 
the binding of SIRT1 to A-type lamins, increases SIRT1 
deacetylase activity and slows down body weight loss and 
significantly extends the life span of Zmpste24−/− mice 
(Liu et al. 2012). However, another study conducted with 
an osteoblast and osteocyte-specific progerin-expressing 
mouse model (Schmidt et al. 2012) did not reveal a ben-
eficial effect of resveratrol (Strandgren et al. 2015). Thus, 
more detailed studies are needed to find out whether res-
veratrol is a potentially promising drug for treatment of 
HGPS.
Concluding remarks
The number of molecular biological studies aiming at the 
identification of lamin-mediated molecular disease mecha-
nisms involved in HGPS increased tremendously following 
the surprising discovery that LMNA is causally linked to the 
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premature aging disease HGPS in 2003. Despite numer-
ous cellular pathways that were identified to be affected by 
the expression of the mutant lamin A protein (Fig. 2), the 
mechanistic details behind these effects are still unclear in 
most cases. Knowledge based on what was already known 
on lamin biology before the protein was linked to HGPS 
and findings on novel roles of lamins in diverse pathways 
in recent years allowed the launch of translational studies 
and the efficient search for drug targets and therapeutic 
approaches within a short time period. The results of the 
first clinical trials taught us that some improvements of the 
disease phenotypes can be achieved by FTI treatment, but 
they also made clear that we need a much better under-
standing of the underlying disease mechanisms to be able 
to tackle specific aspects of the disease in a more focused 
approach. It will also be important to elucidate which of 
the numerous pathways found to be impaired in HGPS are 
most relevant for and causally involved in the pathologies, 
and which ones are just bystanders.
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